{"id":885537,"date":"2026-06-22T19:47:22","date_gmt":"2026-06-22T19:47:22","guid":{"rendered":"https:\/\/www.europesays.com\/us\/885537\/"},"modified":"2026-06-22T19:47:22","modified_gmt":"2026-06-22T19:47:22","slug":"new-drug-combo-may-preserve-muscle-during-weight-loss","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/885537\/","title":{"rendered":"New drug combo may preserve muscle during weight loss"},"content":{"rendered":"

(NewsNation<\/a>) \u2014 A recent trial suggests apitegromab, when used alongside tirzepatide<\/a>, may help preserve lean body mass while supporting overall weight loss.<\/p>\n

The analysis, published<\/a> in Nature, found apitegromab \u2014 a monoclonal antibody \u2014 targets myostatin to help maintain muscle mass when combined with the GLP-1 medication. Apitegromab works by inhibiting the activation of myostatin, a protein that limits skeletal muscle growth, according<\/a> to Medscape.<\/p>\n

\u201cResults from EMBRAZE demonstrate clinical proof of concept for a highly selective anti-myostatin antibody to preserve lean mass with tirzepatide therapy,\u201d the study authors said.<\/p>\n

Which GLP-1 works best? New meta-study puts them head-to-head <\/a><\/p>\n

Researchers studied 102 adults<\/a> with overweight or obesity over 24 weeks. Participants received tirzepatide combined with either apitegromab or a placebo.<\/p>\n

The results showed<\/a> those receiving apitegromab lost less lean mass compared with participants given a placebo. Researchers said about 85% of total weight loss among the apitegromab group came from fat.<\/p>\n

Adverse events were reported in 76% of participants receiving apitegromab and 71% of those receiving a placebo.<\/p>\n

The study excluded individuals with conditions such as diabetes, heart disease, stroke, vascular disorders or active cancer.<\/p>\n

Copyright 2026 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.<\/p>\n

For the latest news, weather, sports, and streaming video, head to The Hill. <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"(NewsNation) \u2014 A recent trial suggests apitegromab, when used alongside tirzepatide, may help preserve lean body mass while…\n","protected":false},"author":3,"featured_media":885538,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[34],"tags":[210,13588,1060,25770,13586,67,132,68,428],"class_list":["post-885537","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-health","tag-lean-body-mass","tag-medication","tag-monoclonal-antibody","tag-muscle-mass","tag-united-states","tag-unitedstates","tag-us","tag-weight-loss"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116795489958124683","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/885537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=885537"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/885537\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/885538"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=885537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=885537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=885537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}